Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00 2022-11-29 am EST
8988.00 JPY   -6.22%
10:50aRare success for Alzheimer's research unlocks hope for future therapies
RE
05:37aEisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
AQ
05:11aChina Outlook, Stronger Yen Upend Tokyo Shares
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Trending : Eisai Shares Rise After Alzheimer's Drug Shows Promise

09/29/2022 | 01:10am EST

0645 GMT - Eisai Co. is the most mentioned company in the news over the past 12 hours, according to Factiva data, after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer's drug significantly slowed the disease's progression in a large study. The drug, called lecanemab, reduced cognitive and functional decline by 27% compared with a placebo. The Japanese pharmaceutical company said it will present detailed study results in November at a research conference and publish them in a peer-reviewed medical journal. The late-stage study has been eagerly anticipated after the failed launch of another Alzheimer's drug, Aduhelm, developed by Eisai and Biogen. Eisai shares rose 14%, building on Wednesday's 17% gain. Dow Jones & Co. owns Factiva. (farah.elias@wsj.com)


(END) Dow Jones Newswires

09-29-22 0310ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.17% 291.41 Delayed Quote.21.67%
EISAI CO., LTD. -6.22% 8988 Delayed Quote.46.75%
All news about EISAI CO., LTD.
10:50aRare success for Alzheimer's research unlocks hope for future therapies
RE
05:37aEisai Announces Approval of Partial Change to Label for Dosage and Administration of Ar..
AQ
05:11aChina Outlook, Stronger Yen Upend Tokyo Shares
MT
02:25aJapan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheime..
MT
02:06aJapanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial
RE
01:53aJapan's Nikkei ends at one-week low on China concerns
RE
11/28Japan's Nikkei hits one-week low on China concerns, Eisai plunge
RE
11/28Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial
DJ
11/28Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial
RE
11/28Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
More news
Financials
Sales 2023 738 B 5 330 M 5 330 M
Net income 2023 57 998 M 419 M 419 M
Net cash 2023 198 B 1 430 M 1 430 M
P/E ratio 2023 46,1x
Yield 2023 1,81%
Capitalization 2 579 B 18 635 M 18 635 M
EV / Sales 2023 3,23x
EV / Sales 2024 3,01x
Nbr of Employees 11 322
Free-Float 93,3%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 988,00 JPY
Average target price 8 461,54 JPY
Spread / Average Target -5,86%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Tatsuyuki Yasuno Manager-Corporate Planning
Yasuhiko Katoh Chairman
Keisuke Naito Executive Officer & Head-Global IT Headquarters
Yasushi Okada Manager-Business Planning
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.46.75%19 801
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
MERCK & CO., INC.41.51%274 964